Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer.[1] Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.[2]
![]() | |
Clinical data | |
---|---|
Other names | Chiauranib; CS-2164 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C27H21N3O3 |
Molar mass | 435.483 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Ibcasertib - Chipscreen Biosciences". AdisInsight. Springer Nature Switzerland AG.
- ^ Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, et al. (March 2017). "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency". Cancer Science. 108 (3): 469–477. doi:10.1111/cas.13141. PMC 5378272. PMID 28004478.